Related Experiment Video
Updated: Oct 9, 2025
06:13
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
Published on: December 1, 2023
1.3K
Ergocalciferol in New-onset Type 1 Diabetes: A Randomized Controlled Trial
Benjamin Udoka Nwosu1, Sadichchha Parajuli1, Gabrielle Jasmin1
1Division of Pediatric Endocrinology, Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA.
Journal of the Endocrine Society
|December 16, 2021
Summary
Vitamin D supplementation with ergocalciferol in type 1 diabetes (T1D) youth reduced inflammation and slowed the rise in HbA1c. This suggests ergocalciferol may protect residual beta-cell function and prolong remission in newly diagnosed T1D.
Area of Science:
- Endocrinology
- Immunology
- Nutritional Science
Background:
- The role of vitamin D in type 1 diabetes (T1D) management is not fully understood.
- Vitamin D possesses anti-inflammatory and immunomodulatory properties.
Purpose of the Study:
- To investigate the impact of ergocalciferol on residual beta-cell function (RBCF) and partial remission (PR) in newly diagnosed T1D youth.
- To test the hypothesis that ergocalciferol supplementation enhances RBCF and extends PR.
Main Methods:
- A 12-month randomized, double-blind, placebo-controlled trial involving 36 youth (10-21 years) with recent T1D diagnosis.
- Participants received either ergocalciferol (50,000 IU weekly then bi-weekly) or a placebo.
- Key metrics included stimulated C-peptide (SCP), HbA1c, and insulin dose-adjusted A1c (IDAA1c).
Main Results:
- Ergocalciferol significantly increased serum 25-hydroxyvitamin D levels and decreased TNF-α concentration.
- No significant differences were observed in SCP or HbA1c between groups.
- However, temporal trends for rising HbA1c and IDAA1c were significantly blunted in the ergocalciferol group.
Conclusions:
- Ergocalciferol supplementation effectively reduced inflammation (TNF-α) and slowed glycemic deterioration (HbA1c, IDAA1c) in newly diagnosed T1D youth.
- These findings suggest a protective effect on residual beta-cell function and partial remission.
- Further research is warranted to confirm these benefits in T1D management.
More Related Videos
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
299
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
299
01:22Diabetes Mellitus: Type 2 and Gestational
3.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.1K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
336
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
336
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
236
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
236
01:22Diabetes Mellitus: Overview and Type I Subtype
3.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.5K
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
308
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
308